F. Hoffmann-La Roche Ltd - Company Profile
Powered by 
All the data and insights you need on F. Hoffmann-La Roche Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date F. Hoffmann-La Roche Ltd Strategy Report
- Understand F. Hoffmann-La Roche Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreBusiness Description
F. Hoffmann-La Roche Ltd (Roche) develops novel medicines that improve the standard of care in infectious diseases, cancer, immunology, ophthalmology, neuroscience, and other conditions. It also specializes in in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management. The company classifies its business into two segments: Pharmaceuticals and Diagnostics.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Through its R&D efforts, Roche strives to develop new products and improve existing ones. The company’s robust R&D capabilities enable it to address unmet medical needs of cancer, cardiometabolic diseases, inflammatory bowel diseases, rare disease, respiratory, hematology, oncology, inflammation and immunological diseases, infectious diseases, ophthalmological diseases, neurological disorders and women’s health. It maintains R&D partnerships worldwide. Through its pharmaceuticals research and early development (pRED) and Genentech research and early development (gRED), the company develops new technologies and drugs. It has R&D centers in Switzerland, the US, the UK, Germany and China. In FY2022, the company spent CHF14,050 million on R&D, which as a percentage of revenue, stood at 22.2%. The company has 18 contract research organisations with 33 research and development sites in Pharmaceuticals and Diagnostics worldwide and 20 manufacturing sites in Pharmaceuticals and Diagnostics worldwide. It has also 32 medicines on the WHO Model of Essential Medicines. It collaborated with investigators from universities in Europe, the US, Asia and Australia.
Business Segments
Overview
Provides medicines for the treatment of immunology, cancer, neuroscience, infectious diseases, haematology, respiratory, eye diseases and others. The company classifies its Pharmaceuticals segment into two sub-segments: Roche Pharmaceuticals (Genentech in the US) and Chugai. Principal pharmaceutical brands include Herceptin and Perjeta for HER2-positive breast cancer and HER2-positive metastatic breast cancer; Actemra/RoActemra for rheumatoid arthritis, systemic juvenile idiopathic arthritis and polyarticular juvenile idiopathic arthritis; Xolair for moderate to severe persistent allergic asthma and chronic idiopathic urticaria; Ocrevus for relapsing and primary progressive forms of multiple sclerosis. Avastin for advanced colorectal, breast, lung, kidney and ovarian cancer, and for relapsed glioblastoma; and MabThera/Rituxan for non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), RA and certain types of ANCA-associated vasculitis; and TNKase/Activase for acute ischemic stroke (AIS) and acute myocardial infarction (AMI). Considers product innovation, acquisitions and partnerships as critical factors for growth.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Provides clinical chemistry and immunoassays, molecular diagnostics, anatomic pathology, point of care diagnostics, laboratory automation and IT solutions, microbiology and hemostasis products, diabetes care, donor screening, urinalysis products, and patient self-testing products and solutions for life science. The Diagnostics segment classified its business into four sub segments: Centralized and Point of Care Solutions, Diabetes Care, Molecular Diagnostics and Tissue Diagnostics. Principal diagnostic brands include cobas (immunodiagnostic, blood screening and virology), Accu-Chek (diabetes care) and Ventana (advanced staining). Envisages product innovation, acquisitions and partnerships as critical factors for growth.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward